"The statement endorses GLP-1 medications (e.g., Semaglutide) for weight management in patients at risk of cardiovascular disease. It emphasizes a four-pillar management approach: nutrition, exercise, medication, and surgery. The guidelines aim to reduce weight stigma and provide a longitudinal care pathway for patients."